A Quantitative Framework for the Structural Validation of N-Size Medical Datasets: Detecting Demographic Bias and Incidence Metric Asymmetries

Read full text Summarise with VIRAT
Authors: Marco Roccetti
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract: The increasing utilization of massive N-size datasets in observational medical research offers unprecedented opportunities for public health analysis; however, the large scale of these databases does not inherently guarantee structural integrity. Without validating fundamental demographic and incidence metrics against national gold standards, there is a significant risk of interpreting structural artifacts as clinical findings. This study proposes a rigorous quantitative framework designed to assess the external validity of large-scale oncological datasets by evaluating three levels of consistency: demographic representativeness, overall crude cancer incidence consistency, and stratum-specific stability within control groups.The application of this methodology to a major national cancer database, used as an exemplar case, reveals a critical epidemiological triple hole that fundamentally undermines the dataset's reliability. Applying our framework has demonstrated a three-dimensional structural discrepancy in the scrutinized dataset: a 32.5% demographic undercount in the elderly population (≥ 65 years), a resulting 26.2% deficit in the cohort’s overall cancer incidence rate, and, most crucially, a 45.1% suppression of expected cancer cases specifically within the control group. This asymmetric deflation has shown how mathematical under-representation in high-risk strata can mechanically inflate relative risk estimates in the exposure group, regardless of the dataset's magnitude. These findings suggest that reported associations in high-profile oncological studies may be statistical anomalies arising from uncorrected selection bias from N-size data rather than genuine biological signals. By quantifying the magnitude of these divergences, this study exemplifies the use of a robust metric to validate the structural integrity of N-size bio-datasets. Implementing such checks against national benchmarks is essential to ensure that observational evidence in oncology big data reflects real-world clinical reality rather than hidden architectural data deficits.

Fields of Study & Subjects

Statistical Methods in Epidemiology Global Cancer Incidence and Screening Meta-analysis and systematic reviews

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 March 2026
Language
EN
Document type
Preprint